Osiris Therapeutics Inc $14.72

down 0.00


25/7/2014 04:00 PM  |  NASDAQ : OSIR  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get OSIR Trend Analysis - it has outperformed the S&P 500 by 12%

Partner Headlines

  1. Journal Publishes Grafix Clinical Study for Chronic Wounds

    Benzinga
  2. Osiris Therapeutics Reports CMS Decides to Package Reimbursement for Products ...

    Benzinga
  3. Osiris Therapeutics Says Trial on Grafix Met All Primary, Secondary Endpoints

    Benzinga
  4. Market Wrap for Monday, October 21: Dow Closes Down, S&P and Nasdaq Close ...

    Benzinga
  5. Mid-Afternoon Market Update: JC Penney Falls on Massive Volume Following ...

    Benzinga
  6. Osiris Legal Team Responds, Says Reviewing All of Legal-Regulatory Options, ...

    Benzinga
  7. Mid-Day Market Update: Hasbro Surges On Upbeat Earnings; Gannett Shares ...

    Benzinga
  8. Mesoblast Acquires Culture Expanded Stem Cell Therapeutic Business from ...

    Benzinga
  9. Market Wrap For October 2: Dollar Moves As Shutdown Continues

    Benzinga
  10. Mid-Afternoon Market Update: Tesla Drops on Baird Downgrade and YouTube ...

    Benzinga
  11. UPDATE: Piper Jaffray Upgrades Osiris Therapeutics, Pull-Back Offers Attractive ...

    Benzinga
  12. Benzinga's Top Pre-Market Gainers

    Benzinga
  13. Mid-Afternoon Market Update: Apple Rises Sharply On Icahn Stake, NASDAQ ...

    Benzinga
  14. UPDATE: Piper Jaffray Downgrades Osiris Therapeutics on DFU Data

    Benzinga
  15. Mid-Day Market Update: US Stocks Edge Higher; Valspar Shares Decline On ...

    Benzinga
  16. Mid-Morning Market Update: Markets Drop, Yum China Same-Store Sales Down ...

    Benzinga
  17. Benzinga's Volume Movers

    Benzinga
  18. Stocks Hitting 52-Week Highs

    Benzinga
  19. Morning Market Movers

    Benzinga
  20. Osiris Reports Strong Efficacy for Grafix to Treat Diabetic Foot Ulcers

    Benzinga
  21. Osiris Therapeutics to Hold Call on Grafix Trial Aug. 13th at 9AM EDT

    Benzinga
  22. Earnings Scheduled For August 5, 2013

    Benzinga
  23. Cell Therapy Might Be Poised For A Comeback

    IBD
  24. Osiris Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  25. Osiris Therapeutics Regains Worldwide Rights to Prochymal and Chondrogen

    Benzinga
  26. Chicago Bridge & Iron Company N.V, Mercadolibre Among Stocks Down on Above-average ...

    FoxBusiness
  27. These Are Four of the Hottest Biotechs in the Market Right Now

    Benzinga
  28. Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression ...

    Benzinga
  29. Health Care Sector Wrap

    FoxBusiness
  30. SBA Communications Corporation, The Ryland Group Among Stocks Hitting 52-Week ...

    FoxBusiness
  31. Arena Pharmaceuticals, Merck &, Other Stocks Hit 52-Week Highs Thursday

    FoxBusiness
  32. 'Biological Legos' Could Become a Blockbuster Innovation for Osiris Therapeutics

    GuruFocus
  33. Osiris Receives Medicare Reimbursement Codes for Grafix

    Benzinga
  34. World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance ...

    Benzinga
  35. Earnings Scheduled For May 11

    Benzinga
  36. Earnings Scheduled For March 9

    Benzinga
Trading Center